Vincent X Liu1,2, Kevin L Winthrop3, Yun Lu1, Husham Sharifi4, Hekmat U Nasiri2, Stephen J Ruoss4. 1. 1 Division of Research, Kaiser Permanente, Oakland, California. 2. 2 Santa Clara Medical Center, Kaiser Permanente, Santa Clara, California. 3. 3 Oregon Health and Science University, Portland, Oregon; and. 4. 4 Stanford University, Stanford, California.
Abstract
RATIONALE: Nontuberculous mycobacterial (NTM) pulmonary disease prevalence is increasing. OBJECTIVES: To determine the association between the use of inhaled corticosteroids and the likelihood of NTM pulmonary infection among individuals with treated airway disease. METHODS: We conducted a case-control study of subjects with airway disease with and without NTM pulmonary infection (based on mycobacterial respiratory cultures) between 2000 and 2010 in northern California. We quantified the use of inhaled corticosteroids, other airway disease medications, and healthcare use within 6 months of NTM pulmonary infection identification. We used 1:10 case-control matching and conditional logistic regression to evaluate the association between the duration and cumulative dosage of inhaled corticosteroid use and NTM pulmonary infection. RESULTS: We identified 248 cases with NTM pulmonary infection with an estimated rate of 16.4 cases per 10,000 subjects treated for airway disease. The median interval between treated airway disease cohort entry (defined as date of patient filling the third airway disease treatment prescription) and NTM case identification was 1,217 days. Compared with control subjects, subjects with NTM pulmonary infection were more likely to use airway disease medications including systemic steroids; they were also more likely to use health care. Any inhaled corticosteroids use between 120 days and 2 years before cohort entry was associated with substantially increased odds of NTM infection. For example, the adjusted odds ratio for NTM infection among inhaled corticosteroid users in a 2-year interval was 2.51 (95% confidence interval, 1.40-4.49; P < 0.01). Increasing cumulative inhaled corticosteroid dose was also associated with greater odds of NTM infection. CONCLUSIONS: Inhaled corticosteroid use, and particularly high-dose inhaled corticosteroid use, was associated with an increased risk of NTM pulmonary infection.
RATIONALE: Nontuberculous mycobacterial (NTM) pulmonary disease prevalence is increasing. OBJECTIVES: To determine the association between the use of inhaled corticosteroids and the likelihood of NTM pulmonary infection among individuals with treated airway disease. METHODS: We conducted a case-control study of subjects with airway disease with and without NTM pulmonary infection (based on mycobacterial respiratory cultures) between 2000 and 2010 in northern California. We quantified the use of inhaled corticosteroids, other airway disease medications, and healthcare use within 6 months of NTM pulmonary infection identification. We used 1:10 case-control matching and conditional logistic regression to evaluate the association between the duration and cumulative dosage of inhaled corticosteroid use and NTM pulmonary infection. RESULTS: We identified 248 cases with NTM pulmonary infection with an estimated rate of 16.4 cases per 10,000 subjects treated for airway disease. The median interval between treated airway disease cohort entry (defined as date of patient filling the third airway disease treatment prescription) and NTM case identification was 1,217 days. Compared with control subjects, subjects with NTM pulmonary infection were more likely to use airway disease medications including systemic steroids; they were also more likely to use health care. Any inhaled corticosteroids use between 120 days and 2 years before cohort entry was associated with substantially increased odds of NTMinfection. For example, the adjusted odds ratio for NTMinfection among inhaled corticosteroid users in a 2-year interval was 2.51 (95% confidence interval, 1.40-4.49; P < 0.01). Increasing cumulative inhaled corticosteroid dose was also associated with greater odds of NTMinfection. CONCLUSIONS: Inhaled corticosteroid use, and particularly high-dose inhaled corticosteroid use, was associated with an increased risk of NTM pulmonary infection.
Authors: Kevin L Winthrop; Erin McNelley; Brian Kendall; Allison Marshall-Olson; Christy Morris; Maureen Cassidy; Ashlen Saulson; Katrina Hedberg Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop Journal: Chest Date: 2017-05-05 Impact factor: 9.410
Authors: Mohammed Al Houqani; Frances Jamieson; Pamela Chedore; Mauli Mehta; Kevin May; Theodore K Marras Journal: Can Respir J Date: 2011 Jan-Feb Impact factor: 2.409
Authors: J Bourbeau; R J Sebaldt; A Day; J Bouchard; A Kaplan; P Hernandez; M Rouleau; A Petrie; G Foster; L Thabane; J Haddon; A Scalera Journal: Can Respir J Date: 2008 Jan-Feb Impact factor: 2.409
Authors: Jadwiga A Wedzicha; Peter M A Calverley; Terence A Seemungal; Gerry Hagan; Zainab Ansari; Robert A Stockley Journal: Am J Respir Crit Care Med Date: 2007-10-04 Impact factor: 21.405
Authors: Barbara P Yawn; Yunfeng Li; Haijun Tian; Jie Zhang; Steve Arcona; Kristijan H Kahler Journal: Int J Chron Obstruct Pulmon Dis Date: 2013-06-27
Authors: Simone K Visser; Peter T P Bye; Greg J Fox; Lucy D Burr; Anne B Chang; Chien-Li Holmes-Liew; Paul King; Peter G Middleton; Graeme P Maguire; Daniel Smith; Rachel M Thomson; Enna Stroil-Salama; Warwick J Britton; Lucy C Morgan Journal: Lung Date: 2019-11-05 Impact factor: 2.584
Authors: Liana Fraenkel; Joan M Bathon; Bryant R England; E William St Clair; Thurayya Arayssi; Kristine Carandang; Kevin D Deane; Mark Genovese; Kent Kwas Huston; Gail Kerr; Joel Kremer; Mary C Nakamura; Linda A Russell; Jasvinder A Singh; Benjamin J Smith; Jeffrey A Sparks; Shilpa Venkatachalam; Michael E Weinblatt; Mounir Al-Gibbawi; Joshua F Baker; Kamil E Barbour; Jennifer L Barton; Laura Cappelli; Fatimah Chamseddine; Michael George; Sindhu R Johnson; Lara Kahale; Basil S Karam; Assem M Khamis; Iris Navarro-Millán; Reza Mirza; Pascale Schwab; Namrata Singh; Marat Turgunbaev; Amy S Turner; Sally Yaacoub; Elie A Akl Journal: Arthritis Care Res (Hoboken) Date: 2021-06-08 Impact factor: 5.178
Authors: Fahim F Pyarali; Michael Schweitzer; Valeria Bagley; Oriana Salamo; Andrea Guerrero; Arash Sharifi; Michael Campos; Andrew Quartin; Mehdi Mirsaeidi Journal: Front Med (Lausanne) Date: 2018-11-06